精神分裂症患者之骨質密度研究

Bone Density in Patients with Schizophrenia

10.29478/TJP.200512.0004

李明儀(Ming-Yin Lee)；邱獻章(Hsien-Jane Chiu)；楊南屏(Nan-Ping Yang)；孫效儒(Hsiao-Ju Sun)；藍祚鴻(Tsuo-Hung Lan)

精神分裂症 ； 骨質密度 ； 跟骨超音波 ； 身體質量指數 ； schizophrenia ； osteoporosis ； QUS ； BMI

台灣精神醫學

19卷4期（2005 / 12 / 01）

289 - 297

繁體中文

Objective: To elucidate whether schizophrenic inpatients in a mental hospital have a decreased bone density, and to analyze the descriptive data on possible risk factors associated with decreased bone density. Methods: In this cross- sectional study, we recruited 121 male and 126 female schizophrenic or schizoaffective patients from chronic wards. Bone mineral density was measured by QUS-2 over calcaneal bone. Descriptive data including age, sex, height, body weight, past medical or surgical history, daily activity level, smoking, and antipsychotics exposure in past two years were collected and analyzed. Results: Although the bone density (BD) of male patients was somewhat higher (measured as BUA=85.3±20.8 dB/MHz), it was not significantly different (t=l.47, df=215, p=0.253) from the BD of female patients (82.5±16.7 dB/MHz). Multiple linear regression revealed that only age and Body Mass Index (BMI) had a significant contribution to the variance of BD. All other possible risk factors surveyed, including smoking, pharmacological treatment, amenorrhea, activity levels, showed no significant influence on BD statistically. Conclusion: Bone density was negatively correlated with age, and positively correlated with BMI. The gender difference in BD observed in normal population was not found in this sample of chronic schizophrenic patients.

Objective: To elucidate whether schizophrenic inpatients in a mental hospital have a decreased bone density, and to analyze the descriptive data on possible risk factors associated with decreased bone density. Methods: In this cross- sectional study, we recruited 121 male and 126 female schizophrenic or schizoaffective patients from chronic wards. Bone mineral density was measured by QUS-2 over calcaneal bone. Descriptive data including age, sex, height, body weight, past medical or surgical history, daily activity level, smoking, and antipsychotics exposure in past two years were collected and analyzed. Results: Although the bone density (BD) of male patients was somewhat higher (measured as BUA=85.3±20.8 dB/MHz), it was not significantly different (t=l.47, df=215, p=0.253) from the BD of female patients (82.5±16.7 dB/MHz). Multiple linear regression revealed that only age and Body Mass Index (BMI) had a significant contribution to the variance of BD. All other possible risk factors surveyed, including smoking, pharmacological treatment, amenorrhea, activity levels, showed no significant influence on BD statistically. Conclusion: Bone density was negatively correlated with age, and positively correlated with BMI. The gender difference in BD observed in normal population was not found in this sample of chronic schizophrenic patients.

1. Ataya K,Mercado A,Kartaginer J,Abbasi A,Mo-ghissi KS(1988).Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia.Fertility and Sterility,50,876-81.
2. Bauer,Douglas C,Gluer,Claus C,Caulesy(1997).Broadband ultrasound attenuation predicts fractures strongly and independently of densimetry ill older women: a prospective study.Arch Intern Med,157,629-34.
3. Becker D,Liver O,Mester R,Rapoport M,Weizman A,Weiss M(2003).Rispendone, but not olanzapine, decrease bone mineral density in female premenopausal schizophrenia patients.J Clin Pyschiatry,64,761-6.
4. Bilici M,Cakirbay H,Guler M,Tosun M,Ulgen M,Tan U(2002).Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.International Journal of Neuroscience,112,817-28.
5. Canuso CM,Goldstein JM,Wojcik J(2002).Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.Psychiatry Research,111,11-20.
6. Cronholm PF,Barr W(2003).Densitometry identifies women in whom treatment will reduce fracture risk.J Fam Pract,52,114-7.
7. Cummings SR,Black DM,Nevitt MC(1993).Bone density at various sites for prediction of hip fractures: the Study of Osteoporotic Fractures Research Group.Lancet,341,72-5.
8. Ettinger,Mark P(2003).Aging bone and osteoporosis: strategies for preventing fractures in the elderly.Intern Med,163,2237-46.
9. Gennari C,Martini G,Nuti R(1998).Secondary osteoporosis.Aging-Clinical & Experimental Research,10,214-24.
10. Halbreich U,Kinon BJ,Gilmore JA, Kahn LS(2003).Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.PNEC,28,53-67.
11. Keely EJ,Reiss JP,Drinkwater DT,Faiman FACE C(1997).Bone mineral density, sex hormones, and longterm use of neuroleptic agents in men.Endocr Pract,3,209-13.
12. Kinon BJ,Gilmore JA,Liu H,Halbreich UM(2003).Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.PNEC,28,55-68.
13. Kiuon BJ,Gilmore JA,Liu H,Halbreich UM(2003).Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.PNEC,28,69-82.
14. Lean M,De Smedt G(2004).Schizophrenia and osteoporosis.Int Clin Psychopharmacol,19,31-5.
15. Maguire G A(2002).Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.J Clin Psychiatry,63,56-62.
16. Naidoo U,Goff DC,Klibanski A(2003).Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents.PNEC,28,97-108.
17. Accessed October
18. Smith S,Wheeler MJ,MulTay R,O`Keane V(2002).The effects of antipsychotic- induced hyperprolactinemia on the hypothalamic-pituitary-gonadal axis.J Clin Psychopharmacol,22,109-14.
19. Stewart A,Reid DM(2002).Quantitative ultrasound in osteoporosis.Seminars in musculoskeletal radiology,6,229-31.
20. U Halbreich, Palter S(1996).: Accelerated osteoporosis in psychiatric patients: possible pathophysiological process.Schizophrenia bulletin,22,447-54.
21. U Halbreich,Rojansky N,Palter S(1995).Decreased bone mineral density in medicated psychiatric Patients.Psychosomatic Medicine,57,485-91.
22. Welch A,Camus J,Dalzell N,Oakes S,Reeve J,Khaw KT(2004).Broadband ultrasound attenuation (BUA) of the heel bone and its correlates in men and women in the EPIC-Norfolk cohort: a crosssectional population-based study.Osteoporos Int,15,217-25.
23. World Health Organization(1994).Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group.World Health Organ Tech Rep Ser,843,1-129.